Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Autor: Della-Fiorentina, S., Begbie, S., Jennens, R., Dass, J., Pittman, K., Ivanova, N., Koynova, T., Petrov, P., Tomova, A., Tzekova, V., Couture, F., Hirsh, V., Burkes, R., Sangha, R., Ambrus, M., Janaskova, T., Musil, J., Novotny, J., Zatloukal, P., Jakesova, J., Klenha, K., Roubec, J., Vanasek, J., Fayette, J., Barlesi, F., Bennouna-Louridi, J., Chouaid, C., Mazières, J., Vallerand, H., Robinet, G., Souquet, P.-J., Spaeth, D., Schott, R., Lena, H., Martinet, Y., El Kouri, C., Baize, N., Scherpereel, A., Molinier, O., Fuchs, F., Josten, K.M., Manegold, C., Marschner, N., Schneller, F., Overbeck, T., Thomas, M., von Pawel, J., Reck, M., Schuette, W., Hagen, V., Schneider, C.-P., Georgoulias, V., Varthalitis, I., Zarogoulidis, K., Syrigos, K., Papandreou, C., Bocskei, C., Csanky, E., Juhasz, E., Losonczy, G., Mark, Z., Molnar, I., Papai-Szekely, Z., Tehenes, S., Vinkler, I., Almel, S., Bakshi, A., Bondarde, S., Maru, A., Pathak, A., Pedapenki, R.M., Prasad, K., Prasad, S.V.S.S., Kilara, N., Gorijavolu, D., Deshmukh, C.D., John, S., Sharma, L.M., Amoroso, D., Bajetta, E., Bidoli, P., Bonetti, A., De Marinis, F., Maio, M., Passalacqua, R., Cascinu, S., Bearz, A., Bitina, M., Brize, A., Purkalne, G., Skrodele, M., Baba, A.A., Ratnavelu, K., Saw, M.H., Samson-Fernando, M.C., Ladrera, G.E., Jassem, J., Koralewski, P., Serwatowski, P., Krzakowski, M., Cebotaru, C., Filip, D., Ganea-Motan, D.E., Ianuli, C.H., Manolescu, I.G., Udrea, A., Burdaeva, O., Byakhov, M., Filippov, A., Lazarev, S., Mosin, I., Orlov, S., Udovitsa, D., Khorinko, A., Protsenko, S., Chang, A., Lim, H.L., Tan, Y.O., Tan, E.H., Bastus Piulats, R., Garcia-Foncillas, J., Valdivia, J., de Castro, J., Domine Gomez, M., Kim, S.W., Lee, J.-S., Kim, H.K., Lee, J.S., Shin, S.W., Kim, D.-W., Kim, Y.-C., Park, K.C., Chang, C.-S., Chang, G.-C., Goan, Y.-G., Su, W.-C., Tsai, C.-M., Kuo, H.-P., Benekli, M., Demir, G., Gokmen, E., Sevinc, A., Crawford, J., Giaccone, G., Haigentz, M., Owonikoko, T., Agarwal, M., Pandit, S., Araujo, R., Vrindavanam, N., Bonomi, P., Berg, A., Wade, J., Bloom, R., Amin, B., Camidge, R., Hill, D., Rarick, M., Flynn, P., Klein, L., Lo Russo, K., Neubauer, M., Richards, P., Ruxer, R., Savin, M., Weckstein, D., Rosenberg, R., Whittaker, T., Richards, D., Berry, W., Ottensmeier, C., Dangoor, A., Steele, N., Summers, Y., Rankin, E., Rowley, K., Giridharan, S., Kristeleit, H., Humber, C., Taylor, P., Ramalingam, S., Perez-Soler, R., Douillard, J.-Y., Thatcher, N., Wang, Y., Pultar, P., Zhu, J., Malik, R.

Publikováno v: In Annals of Oncology November 2013 24(11):2875-2880

Clinical significance of germline cancer predisposing variants in unselected patients with pancreatic adenocarcinoma

Autor: Fountzilas, E. Eliades, A. Koliou, G.-A. Achilleos, A. Loizides, C. Tsangaras, K. Pectasides, D. Sgouros, J. Papakostas, P. Rallis, G. Psyrri, A. Papadimitriou, C. Oikonomopoulos, G. Ferentinos, K. Koumarianou, A. Zarkavelis, G. Dervenis, C. Aravantinos, G. Bafaloukos, D. Kosmidis, P. Papaxoinis, G. Theochari, M. Varthalitis, I. Kentepozidis, N. Rigakos, G. Saridaki, Z. Nikolaidi, A. Christopoulou, A. Fostira, F. Samantas, E. Kypri, E. Ioannides, M. Koumbaris, G. Fountzilas, G. Patsalis, P.C.

Our aim was to determine the prevalence, prognostic and predictive role of germline pathogenic/likely pathogenic variants (P/LPVs) in cancer predisposing genes in patients with pancreatic ductal adenocarcinoma (PDAC). Germline testing of 62 cancer su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::5864e6da63cd0cd5e6eff599f06b8ecf
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076668

Pathogenic mutations and overall survival in 3,084 patients with cancer: The Hellenic Cooperative oncology group precision medicine initiative

Autor: Fountzilas, E. Kotoula, V. Koliou, G.-A. Giannoulatou, E. Gogas, H. Papadimitriou, C. Tikas, I. Zhang, J. Papadopoulou, K. Zagouri, F. Christodoulou, C. Koutras, A. Makatsoris, T. Chrisafi, S. Linardou, H. Varthalitis, I. Papatsibas, G. Razis, E. Papakostas, P. Samantas, E. Aravantinos, G. Bafaloukos, D. Kosmidis, P. Koumarianou, A. Psyrri, A. Pentheroudakis, G. Pectasides, D. Futreal, A. Fountzilas, G. Tsimberidou, A.M.

Background: We evaluated the association between pathogenic mutations and overall survival (OS) in patients with cancer referred to Hellenic Cooperative Oncology Group–affiliated Departments. Patients and methods: Patients referred from 12/1980 to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::57331090d89432b306e2791edb40ed33
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105211

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping

Autor: Papaxoinis, G. Kotoula, V. Giannoulatou, E. Koliou, G.-A. Karavasilis, V. Lakis, S. Koureas, A. Bobos, M. Chalaralambous, E. Daskalaki, E. Chatzopoulos, K. Tsironis, G. Pazarli, E. Chrisafi, S. Samantas, E. Kaklamanos, I.G. Varthalitis, I. Konstantara, A. Syrigos, K.N. Pentheroudakis, G. Pectasides, D. Fountzilas, G.

This clinical trial assessed the efficacy and toxicity of panitumumab combined with oxaliplatin and capecitabine as first-line treatment in KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. Patients with exon 2 KRAS wild-type mCRC r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::752c98c8a237b1fb977312a706756b32
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086795

Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG)

Autor: Bamias, A. Peroukidis, S. Stamatopoulou, S. Tzannis, K. Koutsoukos, K. Andreadis, C. Bozionelou, V. Pistalmatzian, N. Papatsoris, A. Stravodimos, K. Varthalitis, I. Karamouzis, M. Milaki, G. Agorastos, A. Kentepozidis, N. Androulakis, N. Bompolaki, I. Kalofonos, H. Mavroudis, D. Dimopoulos, M.A.

Background Advanced urothelial cancer (AUCa) is associated with poor long-term survival. Two major concerns are related to nonexposure to cisplatin-based chemotherapy and poor outcome after relapse. Our purpose was to record patterns of practice in A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::7b5732d6e367cf8e45624a1e3ac0dd7a
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3124495